Ontogeny of human hepatic cytochromes P450

Journal of Biochemical and Molecular Toxicology

Volumn 21, Issue 4, 2007, Pages 169-175

  Hines, Ronald N ^a  

^a CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

Age factors; CYP2C19; CYP2C9; CYP2E1; CYP3A4; CYP3A5; CYP3A7; Cytochrome P450; Developmental pharmacology; Ontogeny

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DRUG METABOLIZING ENZYME; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYP3A7 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ADOLESCENCE; ADOLESCENT; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; FETUS; FETUS DEVELOPMENT; HUMAN; HUMAN DEVELOPMENT; HUMAN TISSUE; INFANCY; INFANT; LIVER; MALE; NEWBORN PERIOD; ONTOGENY; PREPUBERTY; PROTEIN EXPRESSION; WESTERN BLOTTING; CHEMISTRY; CHILD; ENZYMOLOGY; GENE EXPRESSION REGULATION; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFANT; LIVER; MIXED FUNCTION OXYGENASES;

EID: 36048959792     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20179     Document Type: Conference Paper

References (19)

1. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003;55:667-686.
2. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - Drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
3. Hines RN, McCarver DG. The ontogeny of human drug metabolizing enzymes: Phase I oxidative enzymes. J Pharmacol Exp Ther 2002;300:355-360.
4. McCarver DG, Hines RN. The ontogeny of human drug metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002;300:361-366.
5. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: A review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006;5:703-718.
6. Nong A, McCarver DG, Hines RN, Krishnan K. Physicologically based modeling of inter-child differences in pharmacokinetics on the basis of subject-specific data on hepatic CYP2E1 levels. Toxicol Appl Pharmacol 2006;214:78-87.
7. Yang F, Tong X, McCarver DG, Hines RN, Beard DA. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006;33:485-518.
8. Sadeque AJM, Eddy AC, Meier GP, Rettie AE. Stereoselective sulfoxidation by human flavin-containing monooxygenase: Evidence for catalytic diversity between hepatic, renal, and fetal forms. Drug Metab Dispos 1992;20:832-839.
9. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 1996;331:145-169.
10. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
11. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004;308:965-974.
12. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber L, Hines RN, McCarver DG. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003;307:402-407.
13. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003;307:573-582.
14. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-213.
15. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
16. Overby LH, Carver GC, Philpot RM. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 1997;106:29-45.
17. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 2005;314:626-635.
18. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81:510-516.
19. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver, evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625-634.